Guilford, Rhône-Poulenc Rorer Inc. deal

GLFD granted RPR worldwide marketing rights, excluding Scandinavia, for its Gliadel Wafer to treat brain cancer. GLFD will receive $7.5 million in cash and $7.5 million in equity at a market premium ...